Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 2;6:32. doi: 10.1038/s41541-021-00291-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Serum samples were collected at 28 days post prime and post boost vaccination in the survival cohort (n = 6) of the prime-boost experimental group. LASV GP-specific IgG antibody titers in twofold serial-diluted sera were measured by ELISA. Horizontal lines indicate mean titers. Statistical significance between the post prime and post boost antibody titers was determined via Wilcoxon matched-pairs signed rank test (*p = 0.0312). b Summary of experimental timeline. VL = vaccination with ChAdOx1-Lassa-GPC (n = 10 per group); VG = vaccination with ChAdOx1-GFP (n = 10); B = blood collection; C = LASV challenge; N = planned necropsy for comparative virology (n = 4 per group); S = survival or study endpoint (after adjustment for loss of animals n = 5, n = 6, and n = 4 for the prime-boost, prime, and control experimental groups, respectively).